1
|
Nehl E, Heilman S, Ku D, Gottfried D, Farmer S, Mannino R, Tyburski E, Sullivan J, Suessmith A, Bassit L, Figueroa J, Wood A, Leong T, Rao A, Rogers B, Jerris R, Park S, Gonzalez M, Frediani J, Morris C, Levy J, Schoof N, Mavigner M, Roback J, Herzegh K, Saakadze N, Ingersoll J, Cheedarla N, Neish A, Hanberry B, Porter C, Esper A, Kempker R, Rebolledo P, McGuinness P, Balagadde F, Gore R, Koren A, Pollock N, Rogers E, Simin K, Hafer N, Picard MA, Ghezzi C, McManus D, Buchholz B, Rostad C, Claveria V, Ramachandra T, Wang YF, Washington C, Stone C, Griffiths M, Schinazi R, Chahroudi A, Vos M, Brand O, Martin G, Lam W. The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change. IEEE Open J Eng Med Biol 2021; 2:142-151. [PMID: 34192286 PMCID: PMC8118690 DOI: 10.1109/ojemb.2021.3070825] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 03/23/2021] [Accepted: 03/23/2021] [Indexed: 12/23/2022] Open
Abstract
Faced with the COVID-19 pandemic, the US system for developing and testing technologies was challenged in unparalleled ways. This article describes the multi-institutional, transdisciplinary team of the “RADxSM Tech Test Verification Core” and its role in expediting evaluations of COVID-19 testing devices. Expertise related to aspects of diagnostic testing was coordinated to evaluate testing devices with the goal of significantly expanding the ability to mass screen Americans to preserve lives and facilitate the safe return to work and school. Focal points included: laboratory and clinical device evaluation of the limit of viral detection, sensitivity, and specificity of devices in controlled and community settings; regulatory expertise to provide focused attention to barriers to device approval and distribution; usability testing from the perspective of patients and those using the tests to identify and overcome device limitations, and engineering assessment to evaluate robustness of design including human factors, manufacturability, and scalability.
Collapse
|
2
|
McGuinness P, Cook N, Bush H, Lind H, Vuijk P, Doyle A, Braaten E. B-09Cognitive and Executive Function Profile in Children and Adolescents with Autism Spectrum Disorder, with and without Specific Learning Disorder. Arch Clin Neuropsychol 2017. [DOI: 10.1093/arclin/acx076.94] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Hawkins LD, Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, Meng Z, Yang H, Mullarkey M, Young DW, Yang H, Rossignol DP, Nault A, Rose J, Przetak M, Chow JC, Gusovsky F. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther 2002; 300:655-61. [PMID: 11805229 DOI: 10.1124/jpet.300.2.655] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
A series of novel, synthetic compounds containing lipids linked to a phosphate-containing acyclic backbone are shown to have similar biological properties to lipopolysaccharide (LPS). These compounds showed intrinsic agonistic properties when tested for their ability to stimulate tumor necrosis factor-alpha in human whole blood and interleukin-6 in U373 human glioblastoma cells without added LPS coreceptor CD14. The presence of the LPS antagonist E5564 completely blocked responses, suggesting that the novel compounds and LPS share a common mechanism of cell activation. Stereoselectivity of the molecules was observed in vitro; compounds with an R,R,R,R-configuration were strongly agonistic, whereas compounds with an R,S,S,R-configuration were much weaker in their activity on human whole blood and U373 cells. We also tested the effect of the compounds in cells transfected with the LPS receptor Toll-like receptor 4 (TLR4), with similar results, further supporting a shared mechanism with LPS. This was confirmed in vivo where the agonists failed to elicit cytokine responses in C3H/HeJ mice lacking TLR4 signaling. Because LPS-like molecules enhance immune responses, the compounds were mixed with tetanus toxoid and administered to mice in an immunization protocol to test for adjuvant activity. They enhanced the generation of specific antibodies against tetanus toxoid. Our results indicate that these unique compounds behave as agonists of TLR4, resulting in responses similar to those elicited by LPS. They display adjuvant activity in vivo and may be useful for the development of vaccine therapies.
Collapse
Affiliation(s)
- Lynn D Hawkins
- Department of Medicinal Chemistry, Signal Transduction Research, Eisai Research Institute, Andover, Massachusetts 01810, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|